Skip to main content
. Author manuscript; available in PMC: 2020 May 7.
Published in final edited form as: Eur Urol. 2019 Jun 6;76(4):418–424. doi: 10.1016/j.eururo.2019.05.010

Fig. 2 -.

Fig. 2 -

Differential expression of selected markers of interest between treatment arms. (A) Heatmap of markers ordered by domain of interest, including cell cycle regulation and neuroendocrine markers (CD56, chromogranin A, Ki67, PTCH), microenvironment interactions (Shh, p-cMET, p-Src, GR), and AR signalling (ARv7, CYP17, PSA, AR-C terminal, AR-N terminal). The expression of each marker in each sample is represented by the number of standard deviations above (red) or below (green) the mean for that gene across all samples. (B) Protein expression of select markers. AAP = abiraterone acetate plus prednisone; AR = androgen receptor, GR = glucocorticoid receptor, LHRHa = luteinising hormone-releasing hormone agonist; PSA = prostate-specific antigen.